Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
20.92
-0.40 (-1.88%)
At close: Jul 2, 2026, 4:00 PM EDT
20.00
-0.92 (-4.40%)
After-hours: Jul 2, 2026, 6:35 PM EDT
Forte Biosciences Earnings Call Transcripts
Fiscal Year 2025
-
FB102 demonstrated statistically significant protection against gluten-induced gut inflammation and symptoms in a phase 1B celiac disease trial, with a favorable safety profile. A phase 2 trial is planned, aiming for broader efficacy and longer gluten challenge, with top-line data expected in 2026.